Description General description A cell-permeable and reversible benzimidazolo compound that acts as a potent and ATP-competitive inhibitor of Chk2 with an IC50 of 15 nM and a Ki of 37 nM. Displays ~ 1,000-fold greater selectivity over Cdk1/B and CK1 (IC50 = 12 µM and 17 µM, respectively) and only weakly affects the activities of a panel of 31 kinases (< 25% inhibition at 10 µM), including Chk1. Shown to rescue both peripheral CD4+ and CD8+ T-cells from γ-irradiation-induced apoptosis with an EC50 of 3 µM and 7.6 µM, respectively. The solid form of this compound (Cat. No. 220486) is also available. Packaging 5 mg in Glass bottle Packaged under inert gas Warning Toxicity: Irritant (B) Physical form Supplied as a 25 mM (5 mg/550 µL) solution of Chk2 Inhibitor II (Cat. No. 220486) in DMSO. Reconstitution Following initial thaw, aliquot and freeze (-20°C). Other Notes Arienti, K. L., et al. 2005. J. Med. Chem.48, 1873.; Description